Rezolve AI arrives at Thursday's August 6 earnings release carrying the most aggressive short positioning of the recent cycle — yet the stock refuses to cooperate with the bear thesis.
The short-side picture has only intensified since last week's notes. Short interest now stands at 14.3% of free float — 43.2 million shares — having surged 12.8% over the past week alone. That represents nearly the full rebuild from a mid-July trough near 25.8 million shares, when brief covering created a fleeting opportunity. The ORTEX short score has climbed every session since July 20, reaching 80.6 — a ranking in roughly the first percentile of the broader universe. Borrow conditions tell the same story: cost to borrow hit 60% APR this week, up 240% in seven days, retracing toward the late-June extremes when CTB briefly touched 211%. Availability is tight at 23%, meaning roughly one share remains for every four already lent out — constraining new short entry without yet triggering a mechanical squeeze. Options traders, however, are reading the situation differently. The put/call ratio is running at 0.25, near the 52-week low of 0.11 and well below its 20-day average of 0.26, flagging a market skewed toward calls rather than downside protection. That divergence — bears adding aggressively while options flow tilts bullish — has defined this stock for weeks and remains unresolved.
The stock itself has given neither side a clean win. RZLV closed Monday at $2.57, up 5.8% on the day and 11.7% on the week, yet still down 9.5% over the past month. The rebound runs counter to the heaviest short accumulation in the cycle, echoing the pattern from the August 1 note when the stock ended the week up 8.9% even as bears dug in. Correlated peers have been mixed: PATH gained 17.7% on the week while AISP fell 12.9%, and QBTS added 11.5% — RZLV's move is more aligned with the AI names that caught a bid than with the laggards, which removes one easy explanation for the recovery.
The fundamental debate is equally unresolved. Bulls point to Rezolve's Brain Commerce platform and projections for 2026 revenue that, if realised, would represent a step-change in scale. Bears cite the ORTEX stock score breakdown as a rebuttal: a Growth pillar of 90 cannot mask a Quality score of 21 or an ROA of -619, and valuation multiples remain deeply negative. The CEO bought shares in April at $4.00 — well above the current price — and a director added a smaller position in May. Neither trade has paid off yet, but the insider net buying of roughly $3.5 million over 90 days signals conviction from within that the market is undervaluing the story.
Thursday's print is therefore a test of which side has read the setup correctly: whether the bear reconstruction at 60% borrow costs can be vindicated by the numbers, or whether another resilient close forces the most crowded short position of the cycle into a difficult reassessment.
See the live data behind this article on ORTEX.
Open RZLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
Rezolve AI has now passed its August 6 earnings print with the short-side story sharply more intense than the contradictory standoff described in last week's notes — short interest has jumped to a new high, borrow…
Rezolve AI arrives at Wednesday's earnings with the same contradiction that has defined the past two weeks — short sellers adding aggressively, options traders buying calls — but with the positions now locked in and…
